BioStem Secures $40M Committed Equity Facility with Roth Principal Investments
BSEM has more than doubled off its 52-week low of $2.251 on elevated volume (8.8× avg).
Summary
BioStem Technologies secured a $40M committed equity facility with Roth Principal Investments, providing optional capital access at a 3-5% discount to market prices over 36 months.
Key Events · Financing and Capital Events · BSEM
-
$40M Committed Equity Facility Signed
On September 18, 2026, BioStem entered into a common stock purchase agreement with Roth Principal Investments, allowing the company to sell up to $40M of shares at its sole discretion over a 36-month term.
-
Pricing at 3-5% Discount to VWAP
Market Open and Intraday purchases are priced at a 3.0% discount to VWAP; Pre-Market and Post-Market purchases carry a 5.0% discount. No shares have been sold yet—the facility is optional.
-
Exchange Cap Limits Dilution to 19.99%
Issuance is capped at 3,585,375 shares (19.99% of outstanding) unless stockholder approval is obtained or the average purchase price equals or exceeds $4.3056, in which case the cap does not apply.
-
$400K Commitment Fee via Withholding
The 1.0% commitment fee ($400,000) is paid through 10% withholding from future purchase proceeds, not upfront cash. If the company terminates within 90 days of closing, the full fee becomes immediately due.
Analysis · BSEM · Life Sciences
A $40 million committed equity facility with Roth Principal Investments gives BioStem Technologies the right—but not the obligation—to sell shares at a 3% to 5% discount to VWAP over a 36-month term. The arrangement arrives at a critical juncture: the company reported a $8.97M Q2 net loss, a going concern warning, and a $10M payment obligation due September 15, 2026, with cash down to $6.96M. Issuance is limited by an Exchange Cap of 3,585,375 shares (19.99% of outstanding) unless stockholder approval is obtained or the average purchase price exceeds $4.3056. The $400,000 commitment fee is paid via 10% withholding from future purchase proceeds, not upfront cash. This is a survival-oriented financing structure that removes near-term liquidity pressure but creates a significant overhang on the stock.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSEM was trading at $4.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.5M. The 52-week trading range was $2.25 to $8.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.